Acadian Asset Management
CRBP icon

Acadian Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Acadian Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349K Sell
37,389
-71,403
-66% -$676K ﹤0.01% 1528
2026
Q1 		$1.02M Buy
108,792
+48,603
+81% +$409K ﹤0.01% 1158
2025
Q4 		$489K Sell
60,189
-23,630
-28% -$292K ﹤0.01% 1308
2025
Q3 		$1.06M Sell
83,819
-68,452
-45% -$651K ﹤0.01% 1039
2025
Q2 		$1.05M Sell
152,271
-37,822
-20% -$275K ﹤0.01% 966
2025
Q1 		$1.01M Buy
+190,093
New +$1.68M ﹤0.01% 937
2024
Q4 		– Sell
-4,283
Closed -$87K – 1724
2024
Q3 		$87K Sell
4,283
-11,571
-73% -$592K ﹤0.01% 1635
2024
Q2 		$716K Buy
+15,854
New +$667K ﹤0.01% 1092
2023
Q1 		– Sell
-9,581
Closed -$31K – 1774
2022
Q4 		$31K Buy
9,581
+6,475
+208% +$24.9K ﹤0.01% 1651
2022
Q3 		$15K Hold
3,106
– – ﹤0.01% 1618
2022
Q2 		$23K Buy
+3,106
New +$30K ﹤0.01% 1601
2022
Q1 		– Sell
-6,134
Closed -$112K – 1661
2021
Q4 		$112K Buy
+6,134
New +$166K ﹤0.01% 1351

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Acadian Asset Management's CRBP Position: Q2 2026 in Review

Acadian Asset Management reduced its Corbus Pharmaceuticals (CRBP) stake by 66% in Q2 2026, selling an estimated $676K and leaving 37,389 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #1528.

Acadian Asset Management first reported a position in CRBP in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.06M in Q3 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Acadian Asset Management held 37,389 shares of Corbus Pharmaceuticals worth $349K as of Q2 2026.
  • Acadian Asset Management sold 71,403 Corbus Pharmaceuticals shares in Q2 2026, an estimated $676K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1528 holding.
  • Acadian Asset Management first reported a position in Corbus Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
  • Acadian Asset Management's Corbus Pharmaceuticals position peaked at $1.06M in Q3 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.